| 1.24 0.02 (1.64%) | 04-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.53  |
1-year : | 1.78 |
| Resists | First : | 1.3 |
Second : | 1.53 |
| Pivot price | 1.26 |
|||
| Supports | First : | 1.21 |
Second : | 1.14 |
| MAs | MA(5) : | 1.25 |
MA(20) : | 1.26 |
| MA(100) : | 1.31 |
MA(250) : | 1.31 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 32.9 |
D(3) : | 46.5 |
| RSI | RSI(14): 43.2 |
|||
| 52-week | High : | 1.7 | Low : | 0.56 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AVRO ] has closed above bottom band by 18.1%. Bollinger Bands are 43.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.27 - 1.27 | 1.27 - 1.28 |
| Low: | 1.18 - 1.19 | 1.19 - 1.2 |
| Close: | 1.21 - 1.22 | 1.22 - 1.23 |
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Sun, 14 Apr 2024
AVROBIO, Inc. (NASDAQ:AVRO) Short Interest Update - MarketBeat
Mon, 01 Apr 2024
Here's Why AVROBIO, Inc. (AVRO) is Poised for a Turnaround After Losing 19.7% in 4 Weeks - Yahoo Movies UK
Sat, 24 Feb 2024
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AVRO, CTLT, DOOR, FANG - GlobeNewswire
Mon, 05 Feb 2024
SHAREHOLDER ALERT: The M&A Class Action Launches Investigation of the Merger - AVRO, CALB, MGRC, VINE - PR Newswire
Tue, 30 Jan 2024
AVRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of AVROBIO, Inc. Is Fair to Shareholders - Business Wire
Tue, 30 Jan 2024
Avrobio's corporate tremor attracts Tectonic for reverse merger - Fierce Biotech
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 45 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 1.6 (%) |
| Held by Institutions | 61.2 (%) |
| Shares Short | 143 (K) |
| Shares Short P.Month | 121 (K) |
| EPS | 0.27 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.11 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -40.7 % |
| Return on Equity (ttm) | 14.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.48 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -63 (M) |
| Levered Free Cash Flow | -36 (M) |
| PE Ratio | 4.59 |
| PEG Ratio | 0 |
| Price to Book value | 0.58 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.89 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|